Your results have been filtered for all content within all Money Map Press subscriptions

Interest rate chatter again dominated the market dialogue this week, as the Fed Open Market Committee again declined to tighten monetary policy during their two-day meeting.

The window is open for a rate hike at the Fed's meeting in September, but, as we noted during our conversation on Wednesday before the central bank's announcement, outside circumstances could affect Yellen and Company's decision.

As we said during our last conversation, the global economy isn't in the best position right now. Oil prices are cratering, impacting the budgets of producer nations. China's stock market is tumbling. Canada is in a recession. Australia's dollar is cratering. And that's just a small sample that doesn't include much needed conversation about Russia, Iran, Brazil, and most of Europe.

 
Your current subscriptions do not allow access to this search result.
Learn More

As we bring another profitable week to a close, it's great to be able to talk about multiple triple-digit "Profit Paychecks" when the markets have been in yo-yo mode and chopping many other traders to pieces...

Earlier today, we took a triple-digit "Profit Paycheck" on the first half of our SPY August 7, 2015 $210 strike calls (SPY150807C00210000).

And our intermediate-term Expedia Inc. (NasdaqGS:EXPE) position had a great earnings report and has rocketed to all-time highs (up 11.5% on the day!). We'll let this run a bit more and see if this momentum breakout can follow through.

Moving on to the markets...

 
Your current subscriptions do not allow access to this search result.
Learn More
Categories:    Stealth Profits Trader

This is going to be short, due to the fact that I'm short on Internet access in a cramped seat of a "luxury" bus. Rest assured, I'll be back early next week with all of the details surrounding today's trade.

We're going to add two big yielding stocks to our portfolio today and add to them on any dips we come across. They're part of a "defensive perimeter" I'm setting up in case the markets can't rally towards new highs and drop 10% or more from here - which, from what I'm seeing, is entirely possible.

 
Your current subscriptions do not allow access to this search result.
Learn More

It's Friday and I'm stuck on a supposedly "luxury" bus, on a long ride in bad traffic.

So, I'm going to have to make this short, but I'll get into all the details for today's trade early next week.

Europe's about to face another crisis. And that means the euro will be under pressure, again.

 
Your current subscriptions do not allow access to this search result.
Learn More

I'm not the easiest guy to impress - especially when it comes to trading systems and strategies. I've just created, reviewed, and critiqued too many of them over the past couple of decades. 

But what our Stealth Stock Trading Indicator (SSTI) has done this month is nothing short of eye-popping.

The S&P 500 continues to trade in its tight sideways box and has whipped other traders around mercilessly with three swings throughout this month.

I'll catalog the markets' whippy moves for you to ponder in my next update, but for now - let's be glad that we're not "other" traders and enjoy ANOTHER 100+% "Profit Paycheck."

 
Your current subscriptions do not allow access to this search result.
Learn More

Many investors view today's markets with a great deal of skepticism - and I don't blame them one iota.

In the last 12 months the S&P500 has only returned 9.3%, so it's no wonder skittish investors are fighting to eke out single-digit gains at best.

We, on the other hand, continue to plow ahead with far superior choices like Gigamon Inc. (NYSE:GIMO), which just traded through the protective stop of $26.00 recommended in Alert #128.

If you've been following along - and I hope you have - you should be out of the second half of the trade for an 87.73% gain... and that's after you've already captured at least 100% on the first half of this trade on April 24, 2015.

Between the two, that's an average return of 93.85% - while the S&P 500 turned in just 9.07% over the same time period.

If you're not yet out of this trade, here's what to do...

 
Your current subscriptions do not allow access to this search result.
Learn More
Categories:    Small-Cap Rocket Alert

I've received several fantastic comments and inquiries over the past week from Money Calendar subscribers. In today's "Mail Bag" video, I tackle the most Frequently Asked Questions.

Whether you asked one of these questions or not, all of my readers can benefit from the answers. Keep those questions coming! They help me continually improve our service.

 
Your current subscriptions do not allow access to this search result.
Learn More

It ranks as the No. 1 killer of adults in the U.S.. It's a condition that affects some 25 million Americans and accounts for more than 14 million visits to a doctor or medical center each year.

Of course, I'm talking about cardiovascular disease (CVD). And make no mistake, this killer is on the rise.

Consider that by 2030, the cost to treat heart disease in the United States will triple, rising from $273 billion to $818 billion.

In addition, industry experts estimate the costs resulting from lost productivity due to cardiovascular disease will climb by 61% in that same period from $172 billion to $276 billion.

We're talking a grand total of all associated CVD costs of a whopping $1.1 trillion. And that's just for the U.S.

 
Your current subscriptions do not allow access to this search result.
Learn More

Yesterday, Sanofi SA (NYSE ADR: SNY) reported a solid second quarter, easily beating analyst forecasts.

Revenue of $10.24 billion was up 4.9% from a year ago. And adjusted net income increased 20% to $2.02 billion.

Most of Sanofi's recent success can be pegged to its work in biotech and the strong sales of that unit's multiple sclerosis drug Aubagio. The French company's biotech unit, Genzyme, posted a 27% rise in revenue.

And all this comes on the heels of the U.S. Food and Drug Administration giving Praluent, Sanofi's brand-new cholesterol-reducing treatment, the green light to be marketed in the United States. That drug, which will launch this week or next, should add at least $1 billion a year to Sanofi's coffers by 2018.

 
Your current subscriptions do not allow access to this search result.
Learn More